The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Open accessAbstract
Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Although the role of CDK2 in tumorigenesis has been controversial, emerging evidence proposes that selective CDK2 inhibition may provide a therapeutic benefit against certain tumors, and it continues to appeal as a strategy to exploit in anticancer drug development. Several small-molecule CDK2 inhibitors have progressed to the clinical trials. However, a CDK2-selective inhibitor is yet to be discovered. Here, we discuss the latest understandings of the role of CDK2 in normal and cancer cells, review the core pharmacophores used to target CDK2, and outline strategies for the rational design of CDK2 inhibitors. We attempt to provide an outlook on how CDK2-selective inhibitors may open new avenues for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Retraction: TGFbeta1 activates c-Jun and Erk1 via alphaVbeta6 integrin.
Luettich, K., & Schmidt, C. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-1 · Cited by 70
RetractedCell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Checkpoints: Controls That Ensure the Order of Cell Cycle Events
Hartwell, L. H., & Weinert, T. A. (1989) · Science · doi:10.1126/science.2683079 · Cited by 3,021
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Malumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
ANIMAL CELL CYCLES AND THEIR CONTROL
Norbury, C., & Nurse, P. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.002301 · Cited by 1,274
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Dhavan, R., & Tsai, L.-H. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096019 · Cited by 1,058
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Pavletich, N. P. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2640 · Cited by 744
De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 729
Cyclin E Ablation in the Mouse
Geng, Y., Yu, Q., Sicinska, E., Das, M., Schneider, J. E., Bhattacharya, S., Rideout, W. M., Bronson, R. T., Gardner, H., & Sicinski, P. (2003) · Cell · doi:10.1016/s0092-8674(03)00645-7 · Cited by 660
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Cyclin E and Survival in Patients with Breast Cancer
Keyomarsi, K., Tucker, S. L., Buchholz, T. A., Callister, M., Ding, Y., Hortobagyi, G. N., Bedrosian, I., Knickerbocker, C., Toyofuku, W., Lowe, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021153 · Cited by 557
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528
Cyclin-dependent kinases regulate the antiproliferative function of Smads
Matsuura, I., Denissova, N. G., Wang, G., He, D., Long, J., & Liu, F. (2004) · Nature · doi:10.1038/nature02650 · Cited by 503
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 461
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 433
Du, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.014 · Cited by 421
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
Polychronopoulos, P., Magiatis, P., Skaltsounis, A.-L., Myrianthopoulos, V., Mikros, E., Tarricone, A., Musacchio, A., Roe, S. M., Pearl, L., Leost, M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031016d · Cited by 380
Wyatt, P. G., Woodhead, A. J., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Davis, D. J., Devine, L. A., Early, T. R., Feltell, R. E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800382h · Cited by 340
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage
Huang, H., Regan, K. M., Lou, Z., Chen, J., & Tindall, D. J. (2006) · Science · doi:10.1126/science.1130512 · Cited by 336
CDK4/6 inhibition in breast cancer: current practice and future directions
Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786451 · Cited by 316
Cyclin C/Cdk3 Promotes Rb-Dependent G0 Exit
Ren, S., & Rollins, B. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00300-9 · Cited by 316
Schulze‐Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J., & Kim, S. (1995) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340220408 · Cited by 279
Bramson, H. N., Corona, J., Davis, S. T., Dickerson, S. H., Edelstein, M., Frye, S. V., Gampe, R. T., Harris, P. A., Hassell, A., Holmes, W. D., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010117d · Cited by 269
Major, M. L., Lepe, R., & Costa, R. H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2649-2661.2004 · Cited by 266
Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Sánchez-Martínez, C., Gelbert, L. M., Lallena, M. J., & de Dios, A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.100 · Cited by 230
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
Hydbring, P., Bahram, F., Su, Y., Tronnersjö, S., Högstrand, K., von der Lehr, N., Sharifi, H. R., Lilischkis, R., Hein, N., Wu, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900121106 · Cited by 225
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
Davies, T. G., Bentley, J., Arris, C. E., Boyle, F. T., Curtin, N. J., Endicott, J. A., Gibson, A. E., Golding, B. T., Griffin, R. J., Hardcastle, I. R., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb842 · Cited by 219
Arris, C. E., Boyle, F. T., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F., Gibson, A. E., Golding, B. T., Grant, S., Griffin, R. J., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990628o · Cited by 215
Physiological Relevance of Cell Cycle Kinases
Malumbres, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00025.2010 · Cited by 213
Rogatsky, I., Trowbridge, J. M., & Garabedian, M. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22296 · Cited by 205
Allosteric small-molecule kinase inhibitors
Wu, P., Clausen, M. H., & Nielsen, T. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.002 · Cited by 204
Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol
Shapiro, G. I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040020 · Cited by 203
Eisenbrand, G., Hippe, F., Jakobs, S., & Muehlbeyer, S. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0579-2 · Cited by 197
Discovery of a Potential Allosteric Ligand Binding Site in CDK2
Betzi, S., Alam, R., Martin, M., Lubbers, D. J., Han, H., Jakkaraj, S. R., Georg, G. I., & Schönbrunn, E. (2011) · ACS Chemical Biology · doi:10.1021/cb100410m · Cited by 188
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
Bettayeb, K., Oumata, N., Echalier, A., Ferandin, Y., Endicott, J. A., Galons, H., & Meijer, L. (2008) · Oncogene · doi:10.1038/onc.2008.191 · Cited by 184
Protein Kinases, Their Function and Implication in Cancer and Other Diseases
Shchemelinin, I., Šefc, L., & Nečas, E. (2006) · Folia Biologica · doi:10.14712/fb2006052030081 · Cited by 182
Poon, R. Y. C., & Hunter, T. (1995) · Science · doi:10.1126/science.270.5233.90 · Cited by 181
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Paruch, K., Dwyer, M. P., Alvarez, C., Brown, C., Chan, T.-Y., Doll, R. J., Keertikar, K., Knutson, C., McKittrick, B., Rivera, J., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100051d · Cited by 175
Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values
Krippendorff, B., Neuhaus, R., Lienau, P., Reichel, A., & Huisinga, W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109336751 · Cited by 173
Kim, K. S., Kimball, S. D., Misra, R. N., Rawlins, D. B., Hunt, J. T., Xiao, H.-Y., Lu, S., Qian, L., Han, W.-C., Shan, W., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0201520 · Cited by 172
The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2‐independent roles
Honda, R., Lowe, E. D., Dubinina, E., Skamnaki, V., Cook, A., Brown, N. R., & Johnson, L. N. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600554 · Cited by 172
Squires, M. S., Feltell, R. E., Wallis, N. G., Lewis, E. J., Smith, D.-M., Cross, D. M., Lyons, J. F., & Thompson, N. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0890 · Cited by 171
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
Molenaar, J. J., Ebus, M. E., Geerts, D., Koster, J., Lamers, F., Valentijn, L. J., Westerhout, E. M., Versteeg, R., & Caron, H. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901418106 · Cited by 167
CDK11 Complexes Promote Pre-mRNA Splicing
Hu, D., Mayeda, A., Trembley, J. H., Lahti, J. M., & Kidd, V. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210057200 · Cited by 166
Echalier, A., Bettayeb, K., Ferandin, Y., Lozach, O., Clément, M., Valette, A., Liger, F., Marquet, B., Morris, J. C., Endicott, J. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700940h · Cited by 162
Siemeister, G., Lücking, U., Wengner, A. M., Lienau, P., Steinke, W., Schatz, C. A., Mumberg, D., & Ziegelbauer, K. B. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0286 · Cited by 161
Mice thrive without Cdk4 and Cdk2
Barrière, C., Santamaría, D., Cerqueira, A., Galán, J., Martín, A., Ortega, S., Malumbres, M., Dubus, P. R., & Barbacid, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.03.001 · Cited by 152
A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors
Barun, O., Nagle, A. S., Adrián, F., Lee, C. R., Ren, P., Wang, X., Sim, T., Xie, Y., Wang, X., Xia, G., et al. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.05.015 · Cited by 147
Santo, L., Vallet, S., Hideshima, T., Cirstea, D. D., Ikeda, H., Pozzi, S., Patel, K. J., Okawa, Y., Görgün, G., Perrone, G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.510 · Cited by 145
Pierson-Mullany, L. K., & Lange, C. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10542-10557.2004 · Cited by 140
Coxon, C. R., Anscombe, E., Harnor, S. J., Martin, M. P., Carbain, B., Golding, B. T., Hardcastle, I. R., Harlow, L. K., Korolchuk, S., Matheson, C. J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01254 · Cited by 137
Goh, K. C., Novotny-Diermayr, V, Hart, S., Ong, L. C., Loh, Y. K., Cheong, A., Tan, Y. C., Hu, C., Jayaraman, R., William, A. D., et al. (2012) · Leukemia · doi:10.1038/leu.2011.218 · Cited by 135
Moon, M. J., Lee, S. K., Lee, J., Song, W. K., Kim, S. W., Kim, J. I., Cho, C., Choi, S. J., & Kim, Y. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.08.008 · Cited by 135
Voit, R., & Grummt, I. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231071698 · Cited by 134
Identification and Characterization of an Irreversible Inhibitor of CDK2
Anscombe, E., Meschini, E., Mora-Vidal, R., Martin, M. P., Staunton, D., Geitmann, M., Danielson, U. H., Stanley, W. A., Wang, L.-Z., Reuillon, T. D., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.018 · Cited by 134
Conroy, A., Stockett, D. E., Walker, D. H., Arkin, M. R., Hoch, U., Fox, J. A., & Hawtin, R. E. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0921-5 · Cited by 131
Brasca, M. G., Amboldi, N., Ballinari, D., Cameron, A. D., Casale, E., Cervi, G., Colombo, M., Colotta, F., Croci, V., D’Alessio, R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9006559 · Cited by 130
Hardcastle, I. R., Arris, C. E., Bentley, J., Boyle, F. T., Chen, Y., Curtin, N. J., Endicott, J., Gibson, A. E., Golding, B. T., Griffin, R. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0311442 · Cited by 130
Feldmann, G., Mishra, A., Bisht, S., Karikari, C. A., Garrido‐Laguna, I., Rasheed, Z. A., Ottenhof, N. A., Dadon, T., Alvarez, H., Fendrich, V., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.7.16475 · Cited by 130
Deans, A. J., Khanna, K. K., McNees, C. J., Mercurio, C., Heierhorst, J., & McArthur, G. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3945 · Cited by 130
Cdk2‐dependent phosphorylation of Id2 modulates activity of E2A‐related transcription factors
Hara, E., Hall, M., & Peters, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.2.332 · Cited by 128
PP1 and PP2A phosphatases – cooperating partners in modulating retinoblastoma protein activation
KOLUPAEVA, V. G., & Janssens, V. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08511.x · Cited by 120
Heathcote, D. A., Patel, H., Kroll, S. H. B., Hazel, P., Periyasamy, M., Alikian, M., Kanneganti, S. K., Jogalekar, A. S., Scheiper, B., Barbazanges, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100732t · Cited by 113
Phosphorylation and activation of B-Myb by cyclin A–Cdk2
Ziebold, U., Bartsch, O., Marais, R., Ferrari, S. M., & Klempnauer, K. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00121-7 · Cited by 113
Ying, M., Shao, X., Jing, H., Liu, Y., Qi, X., Cao, J., Chen, Y., Xiang, S., Song, H., Hu, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813139 · Cited by 108
Type II Inhibitors Targeting CDK2
Alexander, L. T., Möbitz, H., Drueckes, P., Savitsky, P. A., Fedorov, O., Elkins, J. M., Deane, C. M., Cowan‐Jacob, S. W., & Knapp, S. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00398 · Cited by 103
CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss
Teitz, T., Fang, J., Goktug, A. N., Bonga, J. D., Diao, S., Hazlitt, R. A., Iconaru, L. I., Morfouace, M., Currier, D. G., Zhou, Y., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20172246 · Cited by 103
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
Yang, L., Fang, D., Chen, H., Lu, Y.-Y., Dong, Z., Ding, H., Jing, Q., Su, S., & Huang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4600 · Cited by 100
Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex
Trowbridge, J. M., Rogatsky, I., & Garabedian, M. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10132 · Cited by 98
Structure-based design of cyclin-dependent kinase inhibitors
Davies, T. G., Pratt, D. J., Endicott, J., Johnson, L. N., & Noble, M. E. M. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00182-1 · Cited by 97
Distinct Activation Pathways Confer Cyclin-Binding Specificity on Cdk1 and Cdk2 in Human Cells
Merrick, K. A., Larochelle, S., Zhang, C., Allen, J. J., Shokat, K. M., & Fisher, R. P. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.10.022 · Cited by 95
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma
Wang, J., Yang, T., Xu, G., Liu, H., Ren, C., Xie, W., & Wang, M. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.08.007 · Cited by 94
A Novel Approach to the Discovery of Small‐Molecule Ligands of CDK2
Martin, M. P., Alam, R., Betzi, S., Ingles, D. J., Zhu, J., & Schönbrunn, E. (2012) · ChemBioChem · doi:10.1002/cbic.201200316 · Cited by 93
Ghia, P., Scarfò, L., Perez, S., Pathiraja, K., Derosier, M., Small, K. A., Sisk, C. M., & Patton, N. W. (2017) · Blood · doi:10.1182/blood-2016-10-748210 · Cited by 91
Mahadevan, D., Plummer, R., Squires, M. S., Rensvold, D., Kurtin, S. E., Pretzinger, C., Dragovich, T., Adams, J., Lock, V., Smith, D.-M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq734 · Cited by 90
Takada, M., Zhang, W., Suzuki, A., Kuroda, T. S., Yu, Z., Inuzuka, H., Gao, D., Wan, L., Zhuang, M., Hu, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1240 · Cited by 90
Chen, Z., Wang, Z., Pang, J. C., Yu, Y., Bieerkehazhi, S., Lu, J., Hu, T., Zhao, Y., Xu, X. Y., Zhang, H., et al. (2016) · Scientific Reports · doi:10.1038/srep29090 · Cited by 89
Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases
Schönbrunn, E., Betzi, S., Alam, R., Martin, M. P., Becker, A., Han, H., Francis, R., Chakrasali, R., Jakkaraj, S., Kazi, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301234k · Cited by 88
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bolin, S., Borgenvik, A., Persson, C., Sundström, A., Qi, J., Bradner, J. E., Weiss, W. A., Cho, Y., Weishaupt, H., & Swartling, F. J. (2018) · Oncogene · doi:10.1038/s41388-018-0135-1 · Cited by 88
Horiuchi, D., Huskey, N. E., Kusdra, L., Wohlbold, L., Merrick, K. A., Zhang, C., Creasman, K. J., Shokat, K. M., Fisher, R. P., & Goga, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111317109 · Cited by 87
Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors
Payton, M. N., Chung, G., Yakowec, P. S., Wong, A., Powers, D., Xiong, L., Zhang, N., Martínez-Leal, J. F., Bush, T. L., Santora, V. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2507 · Cited by 86
Cyclin-Dependent Kinase 2 Controls Peripheral Immune Tolerance
Chunder, N., Wang, L., Chen, C., Hancock, W. W., & Wells, A. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202313 · Cited by 84
Imidazo[1,2- b ]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors
Byth, K. F., Cooper, N., Culshaw, J. D., Heaton, D. W., Oakes, S. E., Minshull, C. A., Norman, R. A., Pauptit, R. A., Tucker, J. A., Breed, J., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.02.008 · Cited by 83
Yun, J., Chae, H.-D., Choi, T., Kim, E. H., Bang, Y., Chung, J., Choi, K. S., Mantovani, R., & Shin, D. Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305178200 · Cited by 82
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas
Ma, Y., Fiering, S., Black, C. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606537104 · Cited by 81
Drug discovery and the human kinome: Recent trends
Eglen, R. M., & Reisine, T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.007 · Cited by 80
From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors
Jautelat, R., Brumby, T., Schäfer, M., Briem, H., Eisenbrand, G., Schwahn, S., Krüger, M., Lücking, U., Prien, O., & Siemeister, G. (2005) · ChemBioChem · doi:10.1002/cbic.200400108 · Cited by 80
Laderian, B., & Fojo, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.006 · Cited by 77
Popowycz, F., Fournet, G., Schneider, C., Bettayeb, K., Ferandin, Y., Lamigeon, C., Tirado, Ò. M., Mateo‐Lozano, S., Notario, V., Colas, P., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801340z · Cited by 76
Hole, A. J., Baumli, S., Shao, H., Shi, S., Huang, S., Pepper, C. J., Fischer, P. M., Wang, S., Endicott, J., & Noble, M. E. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301495v · Cited by 76
Self-citationTriazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: Protein structure-guided design and SAR
Richardson, C. M., Williamson, D. S., Parratt, M. J., Borgognoni, J., Cansfield, A. D., Dokurno, P., Francis, G. L., Howes, R., Moore, J. D., Murray, J. B., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.11.048 · Cited by 75
Cherukupalli, S., Chandrasekaran, B., Kryštof, V., Aleti, R. R., Sayyad, N., Merugu, S. R., Kushwaha, N. D., & Karpoormath, R. V. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.02.030 · Cited by 73
Chen, E. X., Hotte, S. J., Hirte, H. W., Siu, L. L., Lyons, J., Squires, M. S., Lovell, S., Turner, S., McIntosh, L., & Seymour, L. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.565 · Cited by 72
Misra, R. N., Xiao, H.-Y., Rawlins, D. B., Shan, W., Kellar, K. A., Mulheron, J. G., Sack, J. S., Tokarski, J. S., Kimball, S. D., & Webster, K. R. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00381-0 · Cited by 71
Singh, U., Chashoo, G., Khan, S. U., Mahajan, P., Nargotra, A., Mahajan, G., Singh, A., Sharma, A., Mintoo, M. J., Guru, S. K., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00663 · Cited by 71
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Azimi, A., Caramuta, S., Seashore-Ludlow, B. A., Boström, J., Robinson, J. L., Edfors, F., Tuominen, R., Kemper, K., Krijgsman, O., Peeper, D. S., et al. (2018) · Molecular Systems Biology · doi:10.15252/msb.20177858 · Cited by 71
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2
Paruch, K., Dwyer, M. P., Alvarez, C., Brown, C. L., Chan, T., Doll, R. J., Keertikar, K. M., Knutson, C. E., McKittrick, B. A., Rivera, J., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.017 · Cited by 68
Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development
Senese, S., Lo, Y., Huang, D., Zangle, T. A., Gholkar, A. A., Robert, L., Homet, B., Ribas, A., Summers, M. K., Teitell, M. A., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.420 · Cited by 68
Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation
Gondeau, C., Gerbal‐Chaloin, S., Bello, P. A., Aldrian, G., Morris, M. C., & Divita, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413690200 · Cited by 67
Beale, G., Haagensen, E. J., Thomas, H. D., Wang, L.-Z., Revill, C., Payne, S. L., Golding, B. T., Hardcastle, I. R., Newell, D. R., Griffin, R. J., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.238 · Cited by 66
Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors
McInnes, C., Wang, S., Anderson, S., O'Boyle, J., Jackson, W., Kontopidis, G. A., Meades, C. K., Mezna, M., THOMAS, M. P., Wood, G., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.022 · Cited by 63
Self-citationLee, K. H., Lee, S., Lee, H. J., Choi, G. E., Jung, Y. H., Kim, D. I., Gabr, A. A., Ryu, J. M., & Han, H. J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00229 · Cited by 62
Identification of CDK2 as a Novel Target in Treatment of Prostate Cancer
Yin, X., Yu, J. J., Zhou, Y., Wang, C., Jiao, Z., Qian, Z., Sun, H. X., & Chen, B. (2018) · Future Oncology · doi:10.2217/fon-2017-0561 · Cited by 57
Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2
Rastelli, G., Anighoro, A., Chripková, M., Carrassa, L., & Broggini, M. (2014) · Cell Cycle · doi:10.4161/cc.29295 · Cited by 56
N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine
Bettayeb, K., Sallam, H., Ferandin, Y., Popowycz, F., Fournet, G., Hassan, M., Echalier, A., Bernard, P., Endicott, J., Joseph, B., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0080 · Cited by 56
4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2
Mesguiche, V., Parsons, R. J., Arris, C. E., Bentley, J., Boyle, F. T., Curtin, N. J., Davies, T. G., Endicott, J., Gibson, A. E., Golding, B. T., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00884-3 · Cited by 56
Structure-based discovery of cyclin-dependent protein kinase inhibitors
Martin, M. P., Endicott, J., & Noble, M. E. M. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170040 · Cited by 56
Structural dissection of cyclin dependent kinases regulation and protein recognition properties
Lolli, G. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11195 · Cited by 53
Seftel, M. D., Kuruvilla, J. G., Kouroukis, T., Banerji, V., Fraser, G. A. M., Crump, M., Kumar, R., Chalchal, H. I., Salim, M., Laister, R. C., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239259 · Cited by 51
A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
Lin, S., Lin, J., Hsueh, C., Chou, T., & Wong, R. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172315 · Cited by 50
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer
Kawakami, M., Mustachio, L. M., Rodriguez‐Canales, J., Mino, B., Roszik, J., Tong, P., Wang, J., Lee, J. J., Myung, J. H., Heymach, J. V., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw297 · Cited by 50
Fueling the Cycle: CDKs in Carbon and Energy Metabolism
Solaki, M., & Ewald, J. C. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00093 · Cited by 49
Perspectives for cancer therapies with cdk2 inhibitors
Wadler, S. (2001) · Drug Resistance Updates · doi:10.1054/drup.2001.0224 · Cited by 47
Echalier, A., Cot, E., Camasses, A., Hodimont, E., Hoh, F., Jay, P., Sheinerman, F. B., Krasińska, L., & Fisher, D. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.06.015 · Cited by 47
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
Rao, S. S., Stoehr, J. R., Đokić, D., Wan, L., Decker, J. T., Konopka, K. E., Thomas, A. L., Wu, J., Kaklamani, V., Shea, L. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20202 · Cited by 47
Inhibition of Cyclin-dependent Kinase-2 Induces Apoptosis in Human Diffuse Large B-cell Lymphomas
Faber, A. C., & Chiles, T. C. (2007) · Cell Cycle · doi:10.4161/cc.6.23.4994 · Cited by 46
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)
Malínková, V., Vylíčil, J., & Kryštof, V. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1045414 · Cited by 46
Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases
Wang, T., Block, M. A., Cowen, S. D., Davies, A. M., Devereaux, E., Gingipalli, L., Johannes, J. W., Larsen, N., Su, Q., Tucker, J. A., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.018 · Cited by 45
Molecular profiling and combinatorial activity of CCT 068127: a potent CDK 2 and CDK 9 inhibitor
Whittaker, S. R., Barlow, C., Martin, M. P., Mancusi, C., Wagner, S., Self, A. J., Barrie, E., Poele, R. T., Sharp, S. Y., Brown, N., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12148 · Cited by 45
Targeting malaria with specific CDK inhibitors
Geyer, J. A., Prigge, S. T., & Waters, N. C. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.07.031 · Cited by 44
HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2
LI, Y., YANG, X. H., FANG, S. J., QIN, C. F., Sun, R., LIU, Z. Y., JIANG, B. Y., Wu, X., & Li, G. (2014) · Oncology Reports · doi:10.3892/or.2014.3668 · Cited by 42
A CDK2 activity signature predicts outcome in CDK2-low cancers
McCurdy, S. R., Pacal, M., Ahmad, M. A. E.-R., & Bremner, R. (2016) · Oncogene · doi:10.1038/onc.2016.409 · Cited by 42
Dwyer, M. P., Paruch, K., Alvarez, C., Doll, R. J., Keertikar, K. M., Duca, J. S., Fischmann, T. O., Hruza, A. W., Madison, V., Lees, E. M., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.018 · Cited by 40
An Inhibitor’s-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States
Echalier, A., Hole, A. J., Lolli, G., Endicott, J., & Noble, M. E. M. (2014) · ACS Chemical Biology · doi:10.1021/cb500135f · Cited by 39
Liu, W., Cai, M.-J., Wang, J.-X., & Zhao, X.-F. (2014) · Endocrinology · doi:10.1210/en.2013-2020 · Cited by 38
Degrassi, A., Russo, M., Nanni, C., Patton, V., Alzani, R., Giusti, A. M., Fanti, S., Ciomei, M., Pesenti, E. A., & Texidó, G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0726 · Cited by 37
Heady, L., Fernández-Serra, M., Mancera, R. L., Joyce, S., Venkitaraman, A. R., Artacho, E., Skylaris, C.-K., Ciacchi, L. C., & Payne, M. C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060190+ · Cited by 35
McIntyre, N. A., McInnes, C., Griffiths, G., Barnett, A. L., Kontopidis, G. A., Slawin, A. M. Z., Jackson, W., THOMAS, M. P., Zheleva, D. I., Wang, S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901660c · Cited by 35
Self-citationHeady, L., Fern, M., Mancera, R. L., Joyce, S. A., Venkitaraman, A. R., Artacho, E., Skylaris, C., Ciacchi, R. L. C., & Payne, M. C. (2006) · Cited by 35
Cyclin-dependent kinase 2 protects podocytes from apoptosis
Saurus, P., Kuusela, S., Dumont, V., Lehtonen, E., Fogarty, C. L., Lassenius, M. I., Forsblom, C. M., Lehto, M. J., Saleem, M. A., Groop, P., et al. (2016) · Scientific Reports · doi:10.1038/srep21664 · Cited by 34
Inhibition of HIV-1 virus replication using small soluble Tat peptides
Agbottah, E. T., Zhang, N., Dadgar, S., Pumfery, A. M., Wade, J. D., Zeng, C., & Kashanchi, F. (2005) · Virology · doi:10.1016/j.virol.2005.09.062 · Cited by 32
Cdk2 catalytic activity is essential for meiotic cell division in vivo
Chauhan, S., Diril, M. K., Lee, J., Bisteau, X., Manoharan, V., Adhikari, D., Ratnacaram, C. K., Janela, B., Noffke, J., Ginhoux, F., et al. (2016) · Biochemical Journal · doi:10.1042/bcj20160607 · Cited by 32
Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia
Moharram, S. A., Shah, K., Khanum, F., Marhäll, A., Gazi, M., & Kazi, J. U. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.019 · Cited by 32
Hamdouchi, C., Keyser, H., Collins, E., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1.3.1 · Cited by 30
Jarry, M., Lecointre, C., Malleval, C., Desrues, L., Schouft, M., Joncour, V. L., Liger, F., Lyvinec, G., Joseph, B., Loaëc, N., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou102 · Cited by 30
Probing an Allosteric Pocket of CDK2 with Small Molecules
Christodoulou, M. S., Caporuscio, F., Restelli, V., Carlino, L., Cannazza, G., Costanzi, E., Citti, C., Presti, L. L., Pisani, P., Battistutta, R., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600474 · Cited by 28
Grishina, I., & Lattes, B. (2005) · Cell Cycle · doi:10.4161/cc.4.8.1918 · Cited by 26
Caporali, S., Alvino, E., Starace, G., Ciomei, M., Brasca, M. G., Levati, L., Garbin, A., Castiglia, D., Covaciu, C., & Bonmassar, E. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.12.009 · Cited by 25
Hu, Y., Li, S., Liu, F., Geng, L., Shu, X. H., & Zhang, J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.08.050 · Cited by 24
Merrick, K. A., & Fisher, R. P. (2010) · Cell Cycle · doi:10.4161/cc.9.4.10732 · Cited by 23
Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases
Jackson, R., Barnett, A. L., McClue, S. J., & Green, S. R. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.1.131 · Cited by 21
Camarillo, J. M., Rose, K. L., Galligan, J. J., Xu, S., & Marnett, L. J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00485 · Cited by 20
Arumugasamy, K., Tripathi, S. K., Shanmugam, R., Suryanarayanan, V., & Singh, S. K. (2014) · Journal of Chemical Biology · doi:10.1007/s12154-014-0124-y · Cited by 13
Štefaniková, A., Klačanová, K., Pilchová, I., Hatok, J., & Račay, P. (2017) · General Physiology and Biophysics · doi:10.4149/gpb_2017030 · Cited by 11
AG-024322 is a multi-targeted CDK inhibitor with potent antitumor activity in vivo
Zhang, C. C., Troche, G. E., Yan, Z., et al. (2005) · Cancer Research · Cited by 9
CYC065, potential therapeutic agent for AML and MLL leukaemia
Frame, S., Saladino, C., Davis, S., Blake, D., & Zheleva, D. I. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.04.027 · Cited by 6
Cited by
Targeting CDK2 in cancer: challenges and opportunities for therapy
Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.001 · Cited by 333
Self-citationTargeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Metadata
- Authors
- Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-12-13
- Volume
- 62
- Issue
- 9
- Pages
- 4233-4251
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2904945363
- Cited by
- 276
- References
- 160
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.